Lung ablation successfully destroys small tumors in roughly 80 to 96% of cases when the tumor is under 2 centimeters, with effectiveness dropping sharply for larger tumors. How “successful” ablation is depends on what you’re measuring: complete tumor destruction after the procedure, whether the cancer comes back at that spot, or how long patients survive afterward. The numbers vary based on tumor size, whether it’s a primary lung cancer or a metastasis from somewhere else, and which ablation technique is used.
Local Control and Complete Ablation Rates
The most immediate measure of success is whether the procedure completely destroys the tumor. Radiofrequency ablation, the most widely studied technique, achieves complete ablation in about 90% of cases overall. But that number hides a critical detail: tumor size matters enormously.
Tumors smaller than 2 cm are successfully ablated in 78 to 96% of cases. Once a tumor exceeds 3 cm, the success rate collapses. One study found complete destruction in all tumors under 3 cm but only 23% of larger ones. This happens because the ablation probes create a zone of tissue destruction roughly 4 to 5 cm in diameter, so smaller tumors can be fully covered with a comfortable margin while larger ones cannot.
For pulmonary metastases (cancers that spread to the lungs from elsewhere), local control rates are generally 80 to 90% across multiple studies. These results are encouraging because patients with lung metastases often have limited treatment options, and ablation can target individual spots without removing lung tissue.
Long-term Survival Numbers
For stage I non-small cell lung cancer, the most common scenario where ablation is used, survival rates range widely depending on the study and technique. Radiofrequency ablation shows 78% survival at one year and 27 to 56% at five years. Cryoablation (which freezes rather than heats the tumor) has reported five-year survival as high as 68% in one study, the highest among non-surgical ablation techniques. For context, patients with stage I lung cancer who receive no treatment at all have about a 50% one-year survival rate, so ablation roughly doubles the odds of being alive at one year.
For lung metastases from colorectal cancer or other primary tumors, five-year survival after ablation is approximately 50% or higher. That’s a meaningful number for patients who often aren’t candidates for repeated surgeries.
How Ablation Compares to Surgery
Surgery remains the gold standard for early-stage lung cancer, but many patients can’t undergo it due to poor lung function, other medical conditions, or advanced age. A meta-analysis of eight studies comparing surgical resection to ablation in stage I lung cancer found no significant difference in overall survival at any point from one to five years. Surgery did show better disease-free survival at one and two years, meaning tumors were less likely to come back in that window, but by three to five years the difference disappeared.
For the smallest tumors (stage IA), the gap narrowed further. Pooled data showed no significant differences in either overall survival or disease-free survival between surgery and ablation at one to three years. This suggests ablation performs closest to surgery when tumors are caught early and small.
One nuance: sublobar resection (removing a small wedge of lung) did outperform radiofrequency ablation specifically at one and two years. So for patients healthy enough for even a minor surgery, that option may offer a short-term edge. But for patients who truly can’t tolerate an operation, ablation delivers comparable long-term results.
Radiofrequency vs. Microwave Ablation
The two most common heat-based techniques are radiofrequency ablation (RFA) and microwave ablation (MWA). A meta-analysis of ten studies found that RFA provided slightly longer overall survival (about 2 months more) and roughly 3 additional months of progression-free survival compared to MWA. The advantage in progression-free survival grew over time, with RFA showing better rates at both one and two years.
However, both techniques had similar rates of complete ablation, recurrence, and complications. RFA procedures take about 6 minutes longer on average. For most patients, the practical difference between the two is modest, and the choice often comes down to the tumor’s location and the treatment center’s expertise.
Recurrence After Ablation
Local recurrence, where the tumor regrows at the original ablation site, is one of the main limitations. Radiofrequency ablation has a local recurrence rate of about 22% for stage I lung cancer. Cryoablation’s locoregional recurrence rate is higher at around 36%, though one large study of 160 cryoablation patients reported just a 0.6% local recurrence rate with a 4.3% total recurrence rate, suggesting technique and patient selection play a huge role.
Doctors monitor for recurrence using imaging scans after the procedure. The ablation zone (the area of destroyed tissue) normally shrinks gradually over time. If it starts growing again after three months, and especially after six months, that’s a strong sign the tumor has come back. When recurrence does happen, repeat ablation is often possible since the procedure is minimally invasive.
Tumor Size Is the Biggest Factor
If there’s one takeaway from the research, it’s that smaller tumors mean better outcomes across every measure. Tumors under 2 cm have the highest complete ablation rates, the lowest recurrence, and survival numbers that approach surgical results. Between 2 and 3 cm, results are still reasonable but decline. Above 3 cm, success rates drop dramatically, and other approaches may be more appropriate.
This size threshold exists because of physics: the ablation probe can only heat or freeze a limited volume of tissue. The goal is to destroy the tumor plus a margin of healthy tissue around it. When the tumor is too large, the margins are inadequate and cancer cells survive at the edges.
Recovery and Complications
One of ablation’s strongest selling points is how quickly patients recover. Most people go home the same day or within 24 hours, and many return to normal activities within a few days. Compare that to lung surgery, which typically requires several days in the hospital and weeks of recovery.
The most common complication is pneumothorax, where air leaks into the space around the lung. This happens in roughly 45% of ablation sessions, which sounds alarming but is mostly manageable. The majority of these are small and resolve on their own. Moderate pneumothorax occurs in about 9% of cases, and severe cases requiring intervention happen about 7% of the time. Other complications like bleeding or infection are less common. Serious, life-threatening complications are rare.
Who Gets the Best Results
Ablation works best for a specific patient profile: someone with early-stage primary lung cancer (stage I, especially IA) or a limited number of lung metastases, with tumors under 3 cm, who either can’t tolerate surgery or prefers a less invasive approach. Patients with primary lung cancer need complete staging, usually with a PET/CT scan, before the procedure to confirm the cancer hasn’t spread, since ablation only treats the local tumor.
The choice between heat-based ablation and cryoablation depends partly on tumor location and patient factors that the treatment team evaluates during consultation. Tumors near the chest wall or major airways, for instance, may be better suited to one technique over another. Age alone isn’t a disqualifier: studies have included patients well into their 80s and even 90s, reflecting the procedure’s tolerability for people who would struggle with surgery.